Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
21
pubmed:dateCreated
2000-11-24
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0027-8874
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
92
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1704-6
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:11058606-Androgen Antagonists, pubmed-meshheading:11058606-Antineoplastic Agents, Hormonal, pubmed-meshheading:11058606-Choice Behavior, pubmed-meshheading:11058606-Cost-Benefit Analysis, pubmed-meshheading:11058606-Disease Progression, pubmed-meshheading:11058606-Drug Costs, pubmed-meshheading:11058606-Gonadotropin-Releasing Hormone, pubmed-meshheading:11058606-Hospital Costs, pubmed-meshheading:11058606-Humans, pubmed-meshheading:11058606-Male, pubmed-meshheading:11058606-Medicare, pubmed-meshheading:11058606-Orchiectomy, pubmed-meshheading:11058606-Prostate-Specific Antigen, pubmed-meshheading:11058606-Prostatic Neoplasms, pubmed-meshheading:11058606-Quality of Life, pubmed-meshheading:11058606-Questionnaires, pubmed-meshheading:11058606-Time Factors, pubmed-meshheading:11058606-Treatment Outcome, pubmed-meshheading:11058606-United States
pubmed:year
2000
pubmed:articleTitle
Role of perspective and other uncertainties in cost-effectiveness assessments in advanced prostate cancer.
pubmed:publicationType
Editorial, Comment